Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by GAM Holding AG

GAM Holding AG trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,625 shares of the medical research company’s stock after selling 722 shares during the period. GAM Holding AG’s holdings in Thermo Fisher Scientific were worth $4,487,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. KLCM Advisors Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $218,000. AlphaCentric Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $2,172,000. Americana Partners LLC lifted its holdings in Thermo Fisher Scientific by 1,217.6% in the 4th quarter. Americana Partners LLC now owns 82,809 shares of the medical research company’s stock worth $43,080,000 after buying an additional 76,524 shares in the last quarter. Sierra Ocean LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at about $40,000. Finally, Meridiem Investment Management Ltd. boosted its holdings in Thermo Fisher Scientific by 14.4% in the fourth quarter. Meridiem Investment Management Ltd. now owns 631,856 shares of the medical research company’s stock valued at $328,719,000 after purchasing an additional 79,555 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.0 %

Shares of NYSE:TMO opened at $532.58 on Tuesday. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market cap of $203.71 billion, a P/E ratio of 32.22, a P/E/G ratio of 3.18 and a beta of 0.77. The stock’s 50-day moving average is $548.51 and its 200-day moving average is $569.90.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has approved a stock buyback program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TMO shares. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Scotiabank upped their target price on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. Bank of America reduced their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Finally, Citigroup boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a research report on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $658.00.

Insiders Place Their Bets

In related news, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares in the company, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now owns 111,192 shares in the company, valued at $58,960,669.92. This represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,125 shares of company stock worth $11,231,699 in the last ninety days. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.